Market reactionShares rose 17% on Nov 4. Investing.com: “Earnings call transcript: Ocugen tops Q3 2026 estimates as shares rise 9%”
Ocugen is a clinical-stage company developing modifier gene therapies for inherited and age-related blindness, led by OCU400 for retinitis pigmentosa; none of its products is approved in the U.S. or Europe.
Ocugen's case rests on three late-stage modifier gene therapies, each given as one subretinal injection. OCU400 for retinitis pigmentosa has enrolled 140 patients in the Phase 3 liMeliGhT trial. Topline data are due in the first quarter of 2027, with a BLA targeted for the second quarter. GARDian3, testing OCU410ST in Stargardt disease, reports in the second quarter of 2027. OCU410 for geographic atrophy began Phase 3 in 2026. Cash of $100.4 million is expected to last into 2028.
Thesis checklist
0 risks need attention
Why it is in this state
The evidence, what would weaken it and the source filing
Why it is in this state
The evidence, what would weaken it and the source filing
Why it is in this state
The evidence, what would weaken it and the source filing
Why it is in this state
The evidence, what would weaken it and the source filing
Next decision point
Tests: OCU400 improves visual function in the Phase 3 trial
Do significantly more OCU400-treated patients than untreated controls gain at least two light levels on the LDNA test?
Strong, inconclusive and weak outcomes
What to look for in the result and how each would move the checklist
Price and material events
Select an event marker to read the update below. Marker colors show Thesis status.
Ocugen's first Phase 3 readout, OCU400 in retinitis pigmentosa, is due early 2027
Gene therapy platform racing three orphan BLAs by 2028; OCU400 Phase 3 readout first proof point, contingent on sustaining $100M
Gene-agnostic RP gene therapy with Phase 3 enrolled and RMAT in hand — pivotal readout determines whether the multi-BLA platform story holds
OCU400's Phase 3 readout in retinitis pigmentosa will determine whether Ocugen's gene-agnostic approach can convert 3-year durability signals into registrational proof
About this history: every entry shows when the Thesis moved and what it said. The reasoning behind each move (the evidence, the analysis and the source filing) and the earnings write-ups are part of a subscription.
Dates, trials and completed outcomes are open to everyone. What each upcoming milestone hinges on is part of a subscription.
Disease areas: Eye diseases, Infectious diseases
Catalyst calendar · Upcoming FDA decisions · Thesis changes
Competitive landscape
10 peers tracked
Cash: Market-data provider estimate; measurement period unavailable.
Debt: Market-data provider estimate; a complete comparable filing balance is unavailable.
Quarterly burn: Estimated from trailing free cash flow; measurement period unavailable.
Net cash and estimated runway require verified matching measurement periods. Missing debt components are not assumed to be zero.
Runway: No underlying guidance available.